
A Safety, Efficacy and Tolerability Study of SEP-225289
Depressive DisorderMajorTo determine the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder

Antidepressant Therapy for Bipolar II Major Depression
Bipolar Type II DisorderThis study examines the relative safety and benefit of antidepressant therapy (versus recommended mood stabilizer therapy)of bipolar type II major depressive episode. We hypothesize that antidepressant therapy will be superior to mood stabilizer therapy with little or no difference in treatment emergent manic symptoms.

A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy...
Depressive DisorderMajorThis study was designed to determine if the novel combination of the SSRI, sertraline, and the NRI reboxetine will increase antidepressant efficacy without sacrificing the favorable safety profile of SSRIs.

A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
Depressive DisorderMajorTo assess the comparative efficacy of sertraline versus venlafaxine XR on measures of quality of life.

Acupuncture for Residual Insomnia Associated With Major Depressive Disorder
InsomniaDepressionThe purpose of this study is to evaluate the clinical effectiveness of acupuncture treatment on residual insomnia in major depressive patients.

Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
Major Depressive Disorder (MDD)The primary objective of this Phase IIa trial is to determine the effective dose and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with major depression disorder (MDD). The secondary objectives of this trial are to evaluate the safety and quality of life in subjects with MDD receiving RX-10100 treatment.

Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill
Drug AbuseSchizophrenia2 moreThe purpose of this study is to determine the effectiveness of a behavioral treatment, contingency management, in reducing stimulant use in persons with serious mental illness.

A Study of CX157 (TriRima) for the Treatment of Depression
Major Depressive DisorderThe purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD). Secondary objectives are to evaluate the safety and tolerability and steady state pharmacokinetic profile of CX157 in these subjects.

Stress Generation and Recurrent Depression: The Role of Differential Treatment Response
DepressionMajor Depressive DisorderDepression affects over one million people in Canada, resulting in $14.4 billion per year in costs to Canadian society. In order to prevent this often lifelong disorder, it is critically important to identify risk factors for the recurrence of depression. A crucial force in maintaining depression is the generation of stressful life events. That is, individuals who have a history of depression are likely to generate the very events that precipitate future depressive episodes (e.g., relationship break-up, fired from job, conflicts with the law) due to negative personality characteristics and disrupted social support networks resulting from previous episodes. This project is the first to test a model that examines the role of negative personality, low social support, and childhood abuse and neglect as risk factors for the generation of stressful life events that predict future depression. We will test this model in a group of patients meeting formal criteria for depression who will be treated and then followed up for 12 months or until depression recurrence. With this long-term design we will be in a unique position to understand how depression is maintained over time, thus suggesting important treatment strategies to prevent depression recurrence.

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
Major Depressive DisorderThe purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder